Ruth Coleman

• Health selection into neighborhoods among patients enrolled in a clinical trial.

  Journal article

  Arcaya MC. et al, (2017), Prev Med Rep, 8, 51 - 54

• Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.

  Journal article

  Holman RR. et al, (2017), Lancet Diabetes Endocrinol

• Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis.

  Journal article

  Malhotra R. et al, (2017), JAMA Intern Med

• Microvascular outcomes in type 2 diabetes - Authors' reply.

  Journal article

  Zoungas S. et al, (2017), Lancet Diabetes Endocrinol, 5

• Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.

  Journal article

  Zoungas S. et al, (2017), Lancet Diabetes Endocrinol, 5, 431 - 437

• Estimating the potential incremental benefits on Type 2 diabetes complications rates of targeting successively lower LDL-cholesterol levels

  Journal article

  Mostafa SA. et al, (2017), DIABETIC MEDICINE, 34, 93 - 93

• Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors?

  Conference paper

  Coleman RL. et al, (2017), DIABETIC MEDICINE, 34, 23 - 23

• Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin.

  Journal article

  Zhou K. et al, (2016), Nat Genet, 48, 1055 - 1059

• Estimated 10-year benefit for diabetes complication rates by 1% HbA(1c) decrements in people with type 2 diabetes and cardiovascular disease

  Conference paper

  Mostafa SA. et al, (2016), DIABETOLOGIA, 59, S543 - S543

• Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes.

  Journal article

  Bethel MA. et al, (2016), Diabet Med, 33, 224 - 230

• Ethnicity and long-term vascular outcomes in Type 2 diabetes: A prospective observational study (UKPDS 83)

  Journal article

  Davis TME. et al, (2014), Diabetic Medicine, 31, 200 - 207

• Evaluation of a self-administered oral glucose tolerance test.

  Journal article

  Bethel MA. et al, (2013), Diabetes Care, 36, 1483 - 1488

• Prognostic significance of silent myocardial infarction in newly diagnosed type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79.

  Journal article

  Davis TM. et al, (2013), Circulation, 127, 980 - 987

• Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes.

  Journal article

  GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group None. et al, (2011), Nat Genet, 43, 117 - 120

• Predicting 6-year mortality risk in patients with type 2 diabetes: response to Wells et al.

  Journal article

  Paul S. et al, (2009), Diabetes Care, 32

• Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular Disease in the EPIC- Norfolk Cohort.

  Journal article

  Simmons RK. et al, (2009), Diabetes Care, 32, 708 - 713

• Impact of using a non-diabetes-specific risk calculator on eligibility for statin therapy in type 2 diabetes.

  Journal article

  Price HC. et al, (2009), Diabetologia, 52, 394 - 397

• Performance of the UKPDS Risk Engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort

  Conference paper

  Simmons RK. et al, (2008), DIABETOLOGIA, 51, S549 - S549

• Are measures of adiposity associated independently with incident cardiovascular disease in individuals with newly diagnosed type 2 diabetes?

  Conference paper

  Coleman RL. and Holman RR., (2007), DIABETOLOGIA, 50, S502 - S503

• Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting.

  Journal article

  Mount Hood 4 Modeling Group None., (2007), Diabetes Care, 30, 1638 - 1646

• Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes.

  Journal article

  Coleman RL. et al, (2007), Diabetes Care, 30, 1292 - 1293

• Framingham equations underestimate cardiovascular risk compared with the UKPDS risk engine in people with Type 2 diabetes

  Journal article

  Price HC. et al, (2007), DIABETIC MEDICINE, 24, 55 - 55

• Estimating cardiovascular disease risk for individuals with Type 2 diabetes: the new UKPDS Risk Engine

  Journal article

  Coleman RL. et al, (2007), DIABETIC MEDICINE, 24, 56 - 56

• Estimating risk of clinically evident neuropathy in Type 2 diabetes: a UKPDS risk equation

  Conference paper

  Coleman RL. et al, (2006), 23, 51 - 51

• Non-HDL cholesterol is less informative than the total-to-HDL cholesterol ratio in predicting cardiovascular risk in type 2 diabetes.

  Journal article

  Holman RR. et al, (2005), Diabetes Care, 28, 1796 - 1797

• A Cardiovascular Risk Calculator for Type 2 Diabetes

  Conference paper

  Coleman RL. et al, (2005), 54, A172 - A172

• Framingham risk equations underestimate coronary heart disease risk in diabetes.

  Journal article

  Stevens RJ. et al, (2005), Diabet Med, 22

• Incident nephropathy in type 2 diabetes: a UKPDS Risk Equation

  Conference paper

  Coleman RL. et al, (2005), DIABETOLOGIA, 48, A32 - A32

• Evaluating SCORE and Framingham fatal coronary heart disease risk equations using UKPDS data

  Conference paper

  Coleman RL. et al, (2004), DIABETOLOGIA, 47, A42 - A42

• Could non-HDL cholesterol replace total/HDL cholesterol ratio to estimate coronary heart disease risk in the UKPDS risk engine?

  Conference paper

  Stevens RJ. et al, (2004), DIABETOLOGIA, 47, A61 - A61

• 40(th) EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004.

  Conference paper

  Veitenhansl M. et al, (2004), Diabetologia, 47, A1 - A464

• Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66.

  Journal article

  Stevens RJ. et al, (2004), Diabetes Care, 27, 201 - 207

• Risk of Heart Failure in Type 2 Diabetes

  Conference paper

  Coleman RL. et al, (2003), 52, A217 - A218

• Forecasting Coronary Case Fatality in Type 2 Diabetes: A UKPDS Risk Engine Equation

  Conference paper

  Stevens RJ. et al, (2002), 51, A172 - A173

• Reductions in Hemoglobin and Packed Cell Volume over 3 Years in UKPDS Patients with Newly Diagnoses Type 2 Diabetes

  Conference paper

  Coleman RL.

Recent Publications

• Health selection into neighborhoods among patients enrolled in a clinical trial.

  Journal article

  Arcaya MC. et al, (2017), Prev Med Rep, 8, 51 - 54

• Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.

  Journal article

  Holman RR. et al, (2017), Lancet Diabetes Endocrinol

• Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis.

  Journal article

  Malhotra R. et al, (2017), JAMA Intern Med

• Microvascular outcomes in type 2 diabetes - Authors' reply.

  Journal article

  Zoungas S. et al, (2017), Lancet Diabetes Endocrinol, 5

• Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.

  Journal article

  Zoungas S. et al, (2017), Lancet Diabetes Endocrinol, 5, 431 - 437